• Gallmetzer Healthcare posted EBITDA of EUR 1.02 million for the first half ended June 30, 2026, on revenue of EUR 34.53 million.
• EBIT reached EUR 453,754, with EBITDA margin at 3.18% of value of production.
• Revenue rose about 6% versus the first half of the prior year, supported by stronger margins across the group.
• Gerhò turnover increased 5.45% with margins up 1.72%, while Promis revenue climbed 3.5% on wider international distribution.
• Intermedical Pharma completed refurbishment of its anaesthetics production site, moving into the machinery-ordering phase.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gallmetzer Healthcare S.p.A. published the original content used to generate this news brief on September 03, 2026, and is solely responsible for the information contained therein.